BankingBusiness

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

  • Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders
  • Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid
  • The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid
  • Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund
  • The company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC)
  • Amniotics has also an, by Läkemedelsverket, approved GMP facility to produce Advanced Therapy Medicinal Products (ATMPs)
Previous article
Swift: Passes on €50 million one-time discount
Next article
Added Health: Raises Over £1M
Laura M
Laura M
Laura is a financial reporter, editor, and researcher with a particular interest in fintech innovation, capital markets, and the evolving global banking landscape.

You May Also Like

FinTech

Swedish Court Delays Judgment in Klarna’s Antitrust Case Against Google

The court's decision is crucial for Klarna's operations in the competitive market.Highlights: Swedish court delays decision on Klarna's...
FinTech

Morgan Stanley Launches Bitcoin ETF, Expanding Crypto Offerings

The investment firm broadens its reach into the cryptocurrency market.Highlights: Morgan Stanley launches a Bitcoin ETF to enhance...
FinTech

HSBC Strengthens Position with Hong Kong Stablecoin Issuer License

The banking giant aims to support digital asset initiatives in the region.Highlights: HSBC receives a stablecoin issuer license...
FinTech

US Treasury Secretary Warns Banks About Anthropic’s New AI Model

Treasury Secretary highlights risks AI poses to financial stability.Highlights: US Treasury Secretary warns banks about the risks of...